Salvage treatment of HCV patients by Sofosbuvir, Daclatasvir, Simeprevir and Ribavirin after repeated treatment failures is associated with SVR and reduced risk of hepatocellular carcinoma

被引：0
|
作者：
Hanafy, A. [1 ]
Abd-Elsalam, S. [2 ]
Soliman, S. [3 ]
机构：
[1] Zagazig Univ, Fac Med, Internal Med Hepatol & Endoscopy Div, Zagazig, Egypt
[2] Tanta Univ, Trop Med, Tanta, Egypt
[3] Menoufia Univ, Publ Hlth, Al Minufya, Egypt
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30805-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-365
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [1] Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin
    Shiffman, Mitchell L.
    James, Amy M.
    Long, April G.
    Alexander, Philip C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (08): : 1179 - 1185
  • [2] Safety and Efficacy of Sofosbuvir in Combination with Daclatasvir or Simeprevir With or Without Ribavirin in the Treatment of Chronic HCV Genotype 4-infected Patients: A Real World Experience
    Babatin, Mohamed A.
    Albenmousa, Ali H.
    Alothmani, Hammad S.
    Alghamdi, Abdullah S.
    Bzeizi, Khalid I.
    Aljaroudi, Mandi E.
    Albiladi, Haziz
    Alsahafi, Ashwaq
    Sanai, Faisal M.
    HEPATOLOGY, 2016, 64 : 999A - 1000A
  • [3] Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis
    Wahid, Braira
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (12) : 2195 - 2197
  • [4] Real life data about sofosbuvir, daclatasvir and ribavirin in the treatment of cirrhotic and non cirrhotic HCV patients
    Zaghloul, M. S.
    Amer, I. F.
    El-Batee, H.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 77 - 78
  • [5] TREATMENT OF HCV WITH SIMEPREVIR ASSOCIATED TO DACLATASVIR IN PATIENTS WITH STAGE 4 AND 5 CHRONIC RENAL FAILURE
    Baliellas, C.
    Marquez-Rodriguez, P.
    Castellote, J.
    Casanovas-Taltavull, T.
    Rota, R.
    Girbau, A.
    Duenas, E.
    Cachero, A.
    Xiol, X.
    de Digestiu, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S751 - S751
  • [6] Treatment of Chronic HCV With Sofosbuvir (SOF) and Simeprevir (SMV) in Patients With Cirrhosis and Contraindications to Peginterferon (PEGINF) and Ribavirin (RBV)
    Shiffman, Mitchell
    James, Amy
    Long, April
    Alexander, Philip
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S154 - S155
  • [7] The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
    Abdelkawy, K. S.
    El-Haggar, S. M.
    Ziada, D. H.
    Ebaid, N. F.
    El-Magd, M. A.
    Elbarbry, F. A.
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [8] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
    G. Shiha
    R. Soliman
    M. ElBasiony
    A. A. Hassan
    N. N. H. Mikhail
    Hepatology International, 2018, 12 : 339 - 347
  • [9] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
    Shiha, G.
    Soliman, R.
    ElBasiony, M.
    Hassan, A. A.
    Mikhail, N. N. H.
    HEPATOLOGY INTERNATIONAL, 2018, 12 (04) : 339 - 347
  • [10] Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
    Mohamed, Hala
    Abd El Ghany, Weal
    Yehia, Reem
    Fouad, Magdy
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 8 (01) : 36 - 41
12345